The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?
作者信息
Younis T, Groom A
机构信息
Dalhousie University, Department of Medicine, QE II Health Sciences Centre, Halifax, NS.
出版信息
Curr Oncol. 2015 Apr;22(2):77-9. doi: 10.3747/co.22.2579.
Abstract
摘要
相似文献
1
The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?辅助性芳香化酶抑制剂的性价比：是时候结束这场争论了吗？
Curr Oncol. 2015 Apr;22(2):77-9. doi: 10.3747/co.22.2579.
2
Economic evaluation of aromatase inhibitors for the treatment of breast cancer.芳香化酶抑制剂治疗乳腺癌的经济学评价。
Expert Rev Pharmacoecon Outcomes Res. 2003 Dec;3(6):773-81. doi: 10.1586/14737167.3.6.773.
3
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.美国临床肿瘤学会关于芳香化酶抑制剂作为激素受体阳性绝经后乳腺癌妇女辅助治疗的技术评估：2004年现状报告
J Clin Oncol. 2005 Jan 20;23(3):619-29. doi: 10.1200/JCO.2005.09.121. Epub 2004 Nov 15.
4
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.接受阿那曲唑辅助芳香化酶抑制剂治疗期间发生急性双侧肺栓塞：病例报告及文献综述
Breast Cancer Res Treat. 2006 Oct;99(3):249-55. doi: 10.1007/s10549-006-9212-1. Epub 2006 Jun 3.
5
Preliminary data from ongoing adjuvant aromatase inhibitor trials.正在进行的芳香化酶抑制剂辅助治疗试验的初步数据。
Clin Cancer Res. 2001 Dec;7(12 Suppl):4397s-4401s; discussion 4411s-4412s.
6
Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.走向激素敏感性乳腺癌的最佳内分泌治疗：初始与序贯辅助芳香化酶抑制
Cancer Lett. 2007 Apr 18;248(2):165-74. doi: 10.1016/j.canlet.2006.07.002. Epub 2006 Aug 21.
7
The emerging role of the new aromatase inhibitors in the treatment of breast cancer.新型芳香化酶抑制剂在乳腺癌治疗中的新作用。
Isr Med Assoc J. 2005 Apr;7(4):257-61.
8
Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.芳香化酶抑制剂用于辅助性及预防性乳腺癌内分泌治疗的试验
Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):900s-5s.
9
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.芳香化酶抑制剂在绝经后乳腺癌女性辅助治疗中的获益。
MedGenMed. 2005 Aug 24;7(3):20.
10
Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.芳香化酶抑制剂——将辅助治疗的益处扩展至他莫昔芬之外。
Breast. 2004 Dec;13 Suppl 1:S3-9. doi: 10.1016/j.breast.2004.09.002.
本文引用的文献
1
Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada.加拿大雌激素受体阳性早期乳腺癌绝经后女性激素疗法的经济学评估
Curr Oncol. 2015 Apr;22(2):84-96. doi: 10.3747/co.22.2120.
2
Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.延长辅助内分泌治疗在激素受体阳性绝经后乳腺癌女性治疗中的成本效益分析
Breast Cancer Res Treat. 2014 Jun;145(2):267-79. doi: 10.1007/s10549-014-2950-6. Epub 2014 Apr 26.
3
A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer.一项关于芳香化酶抑制剂与他莫昔芬在早期乳腺癌中成本效益分析的系统评价和方法学评估。
PLoS One. 2013 May 6;8(5):e62614. doi: 10.1371/journal.pone.0062614. Print 2013.
4
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.美国临床肿瘤学会临床实践指南：激素受体阳性乳腺癌患者辅助内分泌治疗的更新。
J Clin Oncol. 2010 Aug 10;28(23):3784-96. doi: 10.1200/JCO.2009.26.3756. Epub 2010 Jul 12.
5
Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review.乳腺癌中芳香化酶抑制剂经济学分析的利益冲突：系统评价。
Breast Cancer Res Treat. 2010 Jun;121(2):273-9. doi: 10.1007/s10549-010-0870-7. Epub 2010 Mar 30.
6
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.芳香化酶抑制剂与他莫昔芬辅助治疗乳腺癌结局的荟萃分析。
J Clin Oncol. 2010 Jan 20;28(3):509-18. doi: 10.1200/JCO.2009.23.1274. Epub 2009 Nov 30.
7
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.从加拿大的角度看，来曲唑与他莫昔芬作为激素受体阳性早期乳腺癌绝经后女性初始辅助治疗的成本效益
Breast Cancer Res Treat. 2008 Apr;108(3):375-87. doi: 10.1007/s10549-007-9607-7. Epub 2007 Jul 26.
8
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.对于绝经后原发性乳腺癌女性，改用依西美坦与继续使用他莫昔芬作为辅助治疗的成本效益。
Cancer. 2007 Aug 1;110(3):499-508. doi: 10.1002/cncr.22824.
9
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.为绝经后乳腺癌女性制定具有成本效益的辅助芳香化酶抑制剂策略的模型构建
Ann Oncol. 2007 Feb;18(2):293-8. doi: 10.1093/annonc/mdl410. Epub 2006 Nov 9.
10
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.绝经后女性乳腺癌辅助激素治疗的成本效益：序贯他莫昔芬-依西美坦与初始阿那曲唑治疗
Breast Cancer Res Treat. 2007 Mar;101(3):325-33. doi: 10.1007/s10549-006-9299-4. Epub 2006 Aug 2.
Zotero 插件